Catechol and aldehyde moieties of 3,4-dihydroxyphenylacetaldehyde contribute to tyrosine hydroxylase inhibition and neurotoxicity

Brain Research

Volumn 1474, Issue , 2012, Pages 100-109

  Vermeer, Lydia M M ^a   Florang, Virginia R ^a   Doorn, Jonathan A ^a  

^a UNIVERSITY OF IOWA   (United States)

Author keywords

Enzyme inhibition; Mitochondrial dysfunction; Parkinson's disease; Structureactivity relationship; Tyrosine hydroxylase

Indexed keywords

ALDEHYDE DERIVATIVE; CATECHOL; HYDROGEN PEROXIDE; LEVODOPA; NITRILE; SUPEROXIDE; TYROSINE 3 MONOOXYGENASE;

ARTICLE; CELL ASSAY; CELL LYSATE; DISORDERS OF MITOCHONDRIAL FUNCTIONS; ENZYME ACTIVITY; ENZYME INHIBITION; HUMAN; HUMAN CELL; MITOCHONDRION; NEUROTOXICITY; PRIORITY JOURNAL; STRUCTURE ANALYSIS;

3,4-DIHYDROXYPHENYLACETIC ACID; ALDEHYDES; CATECHOLS; CELL LINE; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DOPAMINERGIC NEURONS; FLOW CYTOMETRY; HUMANS; PARKINSON DISEASE; STRUCTURE-ACTIVITY RELATIONSHIP; TYROSINE 3-MONOOXYGENASE;

EID: 84865524584     PISSN: 00068993     EISSN: 18726240     Source Type: Journal    
DOI: 10.1016/j.brainres.2012.07.048     Document Type: Article

References (45)

1. M. Akagawa, Y. Ishii, T. Ishii, T. Shibata, M. Yotsu-Yamashita, K. Suyama, and K. Uchida Metal-catalyzed oxidation of protein-bound dopamine Biochemistry 45 2006 15120 15128
2. J.K. Andersen Oxidative stress in neurodegeneration: cause or consequence? Nat. Med. 10 2004 S18 S25 Suppl
3. D.G. Anderson, S.V. Mariappan, G.R. Buettner, and J.A. Doorn Oxidation of 3,4-dihydroxyphenylacetaldehyde, a toxic dopaminergic metabolite, to a semiquinone radical and an ortho-quinone J. Biol. Chem. 286 2011 26978 26986
4. W.J. Burke 3,4-dihydroxyphenylacetaldehyde: a potential target for neuroprotective therapy in Parkinson's disease Curr. Drug Targets: CNS Neurol. Disord. 2 2003 143 148
5. W.J. Burke, S.W. Li, E.A. Williams, R. Nonneman, and D.S. Zahm 3,4-dihydroxyphenylacetaldehyde is the toxic dopamine metabolite in vivo: implications for Parkinson's disease pathogenesis Brain Res. 989 2003 205 213
6. K.P. Datla, S.B. Blunt, and D.T. Dexter Chronic l-DOPA administration is not toxic to the remaining dopaminergic nigrostriatal neurons, but instead may promote their functional recovery, in rats with partial 6-OHDA or FeCl(3) nigrostriatal lesions Mov. Disord. 16 2001 424 434
7. G. Eisenhofer, A. Aneman, D. Hooper, C. Holmes, D.S. Goldstein, and P. Friberg Production and metabolism of dopamine and norepinephrine in mesenteric organs and liver of swine Am. J. Physiol. 268 1995 G641 G649
8. J.D. Elsworth, and R.H. Roth Dopamine synthesis, uptake, metabolism, and receptors: relevance to gene therapy of Parkinson's disease Exp. Neurol. 144 1997 4 9
9. H. Esterbauer, R.J. Schaur, and H. Zollner Chemistry and biochemistry of 4-hydroxynonenal, malonaldehyde and related aldehydes Free Radical Biol. Med. 11 1991 81 128
10. B.H. Falkenburger, and J.B. Schulz Limitations of cellular models in Parkinson's disease research J. Neural. Transm. Suppl. 2006 261 268
11. S.M. Fleming, P.O. Fernagut, and M.F. Chesselet Genetic mouse models of parkinsonism: strengths and limitations NeuroRX 2 2005 495 503
12. L.G. Gahn, and R. Roskoski Jr. Tyrosine hydroxylase activity and extrinsic fluorescence changes produced by polyanions Biochem. J. 295 1993 189 194
13. A. Helander, and O. Tottmar Reactions of biogenic aldehydes with hemoglobin Alcohol 6 1989 71 75
14. Y. Hirata, K. Adachi, and K. Kiuchi Activation of JNK pathway and induction of apoptosis by manganese in PC12 cells J. Neurochem. 71 1998 1607 1615
15. Y. Jinsmaa, V.R. Florang, J.N. Rees, D.G. Anderson, S. Strack, and J.A. Doorn Products of oxidative stress inhibit aldehyde oxidation and reduction pathways in dopamine catabolism yielding elevated levels of a reactive intermediate Chem. Res. Toxicol. 22 2009 835 841
16. M. Kitazawa, V. Anantharam, and A.G. Kanthasamy Dieldrin-induced oxidative stress and neurochemical changes contribute to apoptopic cell death in dopaminergic cells Free Radical Biol. Med. 31 2001 1473 1485
17. B.S. Kristal, A.D. Conway, A.M. Brown, J.C. Jain, P.A. Ulluci, S.W. Li, and W.J. Burke Selective dopaminergic vulnerability: 3,4- dihydroxyphenylacetaldehyde targets mitochondria Free Radical Biol. Med. 30 2001 924 931
18. D.M. Kuhn, R.E. Arthur Jr.; D.M. Thomas, and L.A. Elferink Tyrosine hydroxylase is inactivated by catechol-quinones and converted to a redox-cycling quinoprotein: possible relevance to Parkinson's disease J. Neurochem. 73 1999 1309 1317
19. N.V. Kulagina, and A.C. Michael Monitoring hydrogen peroxide in the extracellular space of the brain with amperometric microsensors Anal. Chem. 75 2003 4875 4881
20. I. Lamensdorf, C. Hrycyna, L.P. He, A. Nechushtan, O. Tjurmina, J. Harvey-White, G. Eisenhofer, E. Rojas, and I.J. Kopin Acidic dopamine metabolites are actively extruded from PC12 cells by a novel sulfonylurea-sensitive transporter Naunyn-Schmiedeberg's Arch. Pharmacol. 361 2000 654 664
21. G. Laschinski, B. Kittner, and M. Brautigam Direct inhibition of tyrosine hydroxylase from PC-12 cells by catechol derivatives Naunyn-Schmiedeberg's Arch. Pharmacol. 332 1986 346 350
22. M.J. LaVoie, B.L. Ostaszewski, A. Weihofen, M.G. Schlossmacher, and D.J. Selkoe Dopamine covalently modifies and functionally inactivates parkin Nat. Med. 11 2005 1214 1221
23. Leviel, V.; Dopamine release mediated by the dopamine transporter, facts and consequences. J Neurochem. 118, 475489.
24. M.B. Mattammal, J.H. Haring, H.D. Chung, G. Raghu, and R. Strong An endogenous dopaminergic neurotoxin: implication for Parkinson's disease Neurodegeneration 4 1995 271 281
25. M.A. Mena, V. Davila, and D. Sulzer Neurotrophic effects of l-DOPA in postnatal midbrain dopamine neuron/cortical astrocyte cocultures J. Neurochem. 69 1997 1398 1408
26. L.M. Mexas, V.R. Florang, and J.A. Doorn Inhibition and covalent modification of tyrosine hydroxylase by 3,4-dihydroxyphenylacetaldehyde, a toxic dopamine metabolite Neurotoxicology 32 2011 471 477
27. M.G. Murer, G. Dziewczapolski, L.B. Menalled, M.C. Garcia, Y. Agid, O. Gershanik, and R. Raisman-Vozari Chronic levodopa is not toxic for remaining dopamine neurons, but instead promotes their recovery, in rats with moderate nigrostriatal lesions Ann. Neurol. 43 1998 561 575
28. S. Mzengeza, and R.A. Whitney Asymmetric induction in nitrone cycloadditions J. Org. Chem. 53 1988 4074 4081
29. T. Nagatsu, M. Levitt, and S. Udenfriend Conversion of l-tyrosine to 3,4-dihydroxyphenylalanine by cell-free preparations of brain and sympathetically innervated tissues Biochem. Biophys. Res. Commun. 14 1964 543 549
30. N.H. Nguyen, C. Cougnon, and F. Gohier Deprotection of arenediazonium tetrafluoroborate ethers with BBr3 J. Org. Chem. 74 2009 3955 3957
31. G.E. Nilsson, and O. Tottmar Biogenic aldehydes in brain: on their preparation and reactions with rat brain tissue J. Neurochem. 48 1987 1566 1572
32. L. Oreland, and C.G. Gottfries Brain and brain monoamine oxidase in aging and in dementia of Alzheimer's type Prog. Neuropsychopharmacol. Biol. Psychiatry 10 1986 533 540
33. M.A. Paz, R. Fluckiger, A. Boak, H.M. Kagan, and P.M. Gallop Specific detection of quinoproteins by redox-cycling staining J. Biol. Chem. 266 1991 689 692
34. R.N. Pittman, S. Wang, A.J. DiBenedetto, and J.C. Mills A system for characterizing cellular and molecular events in programmed neuronal cell death J. Neurosci. 13 1993 3669 3680
35. J.N. Rees, V.R. Florang, D.G. Anderson, and J.A. Doorn Lipid peroxidation products inhibit dopamine catabolism yielding aberrant levels of a reactive intermediate Chem. Res. Toxicol. 20 2007 1536 1542
36. J.N. Rees, V.R. Florang, L.L. Eckert, and J.A. Doorn Protein reactivity of 3,4-dihydroxyphenylacetaldehyde, a toxic dopamine metabolite, is dependent on both the aldehyde and the catechol Chem. Res. Toxicol. 22 2009 1256 1263
37. R.F. Seegal, K. Brosch, B. Bush, M. Ritz, and W. Shain Effects of Aroclor 1254 on dopamine and norepinephrine concentrations in pheochromocytoma (PC-12) cells Neurotoxicology 10 1989 757 764
38. T.J. Shafer, and W.D. Atchison Transmitter, ion channel and receptor properties of pheochromocytoma (PC12) cells: a model for neurotoxicological studies Neurotoxicology 12 1991 473 492
39. D.M. Stone, D.C. Stahl, G.R. Hanson, and J.W. Gibb The effects of 3,4-methylenedioxymethamphetamine (MDMA) and 3,4-methylenedioxyamphetamine (MDA) on monoaminergic systems in the rat brain Eur. J. Pharmacol. 128 1986 41 48
40. S. Strack Overexpression of the protein phosphatase 2A regulatory subunit Bgamma promotes neuronal differentiation by activating the MAP kinase (MAPK) cascade J. Biol. Chem. 277 2002 41525 41532
41. T.N. Taylor, W.M. Caudle, and G.W. Miller VMAT2-deficient mice display nigral and extranigral pathology and motor and nonmotor symptoms of Parkinson's disease Parkinsons Dis. 2011 2011 124165
42. F. Ungar, B. Tabakoff, and S.G. Alivisatos Inhibition of binding of aldehydes of biogenic amines in tissues Biochem. Pharmacol. 22 1973 1905 1913
43. M.C. Wey, E. Fernandez, P.A. Martinez, P. Sullivan, D.S. Goldstein, and R. Strong Neurodegeneration and motor dysfunction in mice lacking cytosolic and mitochondrial aldehyde dehydrogenases: implications for Parkinson's disease PLoS One 7 2012 e31522
44. Y. Xu, A.H. Stokes, R. Roskoski Jr.; and K.E. Vrana Dopamine, in the presence of tyrosinase, covalently modifies and inactivates tyrosine hydroxylase J. Neurosci. Res. 54 1998 691 697
45. D. Yang, and C. Zhang Ruthenium-catalyzed oxidative cleavage of olefins to aldehydes J. Org. Chem. 66 2001 4814 4818